View in EDS

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.

Saved in:
Bibliographic Details
Title: Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Authors: You B; Université Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Sud, EMR UCBL/HCL 3738, Lyon, France GINECO, Paris, France.; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO-GINEGEPS, Lyon, France., Purdy C; Clinical Trial Development Division, Biostatistics and Bioinformatics Department, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Copeland LJ; The Ohio State University, James Cancer Hospital, Columbus, OH., Swisher EM; Division of Gynecologic Oncology, Department of Ob/Gyn, University of Washington, Seattle, WA., Bookman MA; Director, Gynecologic Oncology Therapeutics, Kaiser Permanente Northern California, San Francisco, CA., Fleming G; Hematology and Oncology, The University of Chicago Medicine, Chicago, IL., Coleman R; Chief Scientific Officer, US Oncology Research, The Woodlands, TX., Randall LM; Division of Gynecologic Oncology, Virginia Commonwealth University, School of Medicine, Richmond, VA., Tewari KS; UC Irvine Medical Center, Orange, CA., Monk BJ; HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ., Mannel RS; The University of Oklahoma, Oklahoma City, OK., Walker JL; The University of Oklahoma, Oklahoma City, OK., Cappuccini F; UC Irvine Medical Center, Orange, CA., Cohn D; The Ohio State University, James Cancer Hospital, Columbus, OH., Muzaffar M; Internal Medicine, East Carolina University, Greenville, NC., Mutch D; Washington University School of Medicine, Siteman Cancer Center, St Louis, MO., Wahner-Hendrickson A; Division of Medical Oncology, Mayo Clinic, Rochester, MN., Martin L; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA.; Mersana Therapeutics, Cambridge, MA., Colomban O; Université Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Sud, EMR UCBL/HCL 3738, Lyon, France GINECO, Paris, France.; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO-GINEGEPS, Lyon, France., Burger RA; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA.; Mersana Therapeutics, Cambridge, MA.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Dec 01; Vol. 40 (34), pp. 3965-3974. Date of Electronic Publication: 2022 Oct 17.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36252167
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22You+B%22">You B</searchLink>; Université Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Sud, EMR UCBL/HCL 3738, Lyon, France GINECO, Paris, France.; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO-GINEGEPS, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Purdy+C%22">Purdy C</searchLink>; Clinical Trial Development Division, Biostatistics and Bioinformatics Department, Roswell Park Comprehensive Cancer Center, Buffalo, NY.<br /><searchLink fieldCode="AU" term="%22Copeland+LJ%22">Copeland LJ</searchLink>; The Ohio State University, James Cancer Hospital, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Swisher+EM%22">Swisher EM</searchLink>; Division of Gynecologic Oncology, Department of Ob/Gyn, University of Washington, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Bookman+MA%22">Bookman MA</searchLink>; Director, Gynecologic Oncology Therapeutics, Kaiser Permanente Northern California, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Fleming+G%22">Fleming G</searchLink>; Hematology and Oncology, The University of Chicago Medicine, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Coleman+R%22">Coleman R</searchLink>; Chief Scientific Officer, US Oncology Research, The Woodlands, TX.<br /><searchLink fieldCode="AU" term="%22Randall+LM%22">Randall LM</searchLink>; Division of Gynecologic Oncology, Virginia Commonwealth University, School of Medicine, Richmond, VA.<br /><searchLink fieldCode="AU" term="%22Tewari+KS%22">Tewari KS</searchLink>; UC Irvine Medical Center, Orange, CA.<br /><searchLink fieldCode="AU" term="%22Monk+BJ%22">Monk BJ</searchLink>; HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ.<br /><searchLink fieldCode="AU" term="%22Mannel+RS%22">Mannel RS</searchLink>; The University of Oklahoma, Oklahoma City, OK.<br /><searchLink fieldCode="AU" term="%22Walker+JL%22">Walker JL</searchLink>; The University of Oklahoma, Oklahoma City, OK.<br /><searchLink fieldCode="AU" term="%22Cappuccini+F%22">Cappuccini F</searchLink>; UC Irvine Medical Center, Orange, CA.<br /><searchLink fieldCode="AU" term="%22Cohn+D%22">Cohn D</searchLink>; The Ohio State University, James Cancer Hospital, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Muzaffar+M%22">Muzaffar M</searchLink>; Internal Medicine, East Carolina University, Greenville, NC.<br /><searchLink fieldCode="AU" term="%22Mutch+D%22">Mutch D</searchLink>; Washington University School of Medicine, Siteman Cancer Center, St Louis, MO.<br /><searchLink fieldCode="AU" term="%22Wahner-Hendrickson+A%22">Wahner-Hendrickson A</searchLink>; Division of Medical Oncology, Mayo Clinic, Rochester, MN.<br /><searchLink fieldCode="AU" term="%22Martin+L%22">Martin L</searchLink>; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA.; Mersana Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Colomban+O%22">Colomban O</searchLink>; Université Lyon, Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Sud, EMR UCBL/HCL 3738, Lyon, France GINECO, Paris, France.; Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, GINECO-GINEGEPS, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Burger+RA%22">Burger RA</searchLink>; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA.; Mersana Therapeutics, Cambridge, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2022 Dec 01; Vol. 40 (34), pp. 3965-3974. <i>Date of Electronic Publication: </i>2022 Oct 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36252167
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.22.01207
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3965
    Titles:
      – TitleFull: Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: You B
      – PersonEntity:
          Name:
            NameFull: Purdy C
      – PersonEntity:
          Name:
            NameFull: Copeland LJ
      – PersonEntity:
          Name:
            NameFull: Swisher EM
      – PersonEntity:
          Name:
            NameFull: Bookman MA
      – PersonEntity:
          Name:
            NameFull: Fleming G
      – PersonEntity:
          Name:
            NameFull: Coleman R
      – PersonEntity:
          Name:
            NameFull: Randall LM
      – PersonEntity:
          Name:
            NameFull: Tewari KS
      – PersonEntity:
          Name:
            NameFull: Monk BJ
      – PersonEntity:
          Name:
            NameFull: Mannel RS
      – PersonEntity:
          Name:
            NameFull: Walker JL
      – PersonEntity:
          Name:
            NameFull: Cappuccini F
      – PersonEntity:
          Name:
            NameFull: Cohn D
      – PersonEntity:
          Name:
            NameFull: Muzaffar M
      – PersonEntity:
          Name:
            NameFull: Mutch D
      – PersonEntity:
          Name:
            NameFull: Wahner-Hendrickson A
      – PersonEntity:
          Name:
            NameFull: Martin L
      – PersonEntity:
          Name:
            NameFull: Colomban O
      – PersonEntity:
          Name:
            NameFull: Burger RA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2022 Dec 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 34
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1